0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 31, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it will report financial
results for the second quarter ending June 30, 2012 on Monday, August 6,
2012, after the U.S. financial markets close.
Management will provide an update on the company,... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 30, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that it has earned a
development milestone payment from GlaxoSmithKline (GSK), totaling $3.2
million. The milestone payment is related to progress in the companies’
collaboration on the use of VaxiRNA™ technology for the... Contine Reading & Discuss→
0 Replies
Related Articles
Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects.
Ther Deliv. 2012 Feb;3(2):245-61
Authors: Seth S, Johns R, Templin MV
Abstract
RNAi-based approaches provide a promising therapeutic modality for the treatment of cancer. The inaccessibility of tumors in different cancer types necessitates the development of... Contine Reading & Discuss→
0 Replies
Related Articles
Relationship between chloroplastic H 2O 2 and the salicylic acid response.
Plant Signal Behav. 2012 Aug 1;7(8)
Authors: Noshi M, Maruta T, Shigeoka S
Abstract
Reactive oxygen species (ROS) act as signaling molecules for regulating plant responses to abiotic and biotic stress and there exist source- and kind-specific... Contine Reading & Discuss→
0 Replies
Related Articles
Molecular biology. Use and abuse of RNAi to study mammalian gene function.
Science. 2012 Jul 27;337(6093):421-2
Authors: Kaelin WG
PMID: 22837515 [PubMed - in process] Contine Reading & Discuss→
